1. Home
  2. MMA vs APRE Comparison

MMA vs APRE Comparison

Compare MMA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMA

Alta Global Group Limited

HOLD

Current Price

$0.49

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMA
APRE
Founded
2013
2006
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.5M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
MMA
APRE
Price
$0.49
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
1.6M
117.4K
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.55
52 Week High
$2.00
$2.22

Technical Indicators

Market Signals
Indicator
MMA
APRE
Relative Strength Index (RSI) 45.16 46.37
Support Level $0.37 $0.75
Resistance Level $0.53 $0.81
Average True Range (ATR) 0.13 0.07
MACD -0.01 -0.00
Stochastic Oscillator 22.05 47.10

Price Performance

Historical Comparison
MMA
APRE

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: